Nathan Robison, MD, presents a case of a 14-year-old male with a progressive hypothalamic low-grade glioma whose newly identified KIAA1549::BRAF fusion informs consideration of next-line treatment options after years of relative stability.
Matthew Cascio, DO, reviews second-line treatment for a case of BRAF V600E-mutated recurrent or refractory pediatric low-grade glioma, following initial combination treatment with dabrafenib and trametinib.
Sameer Farouk Sait, MBBS, reviews a case of focal BRAF fusion–positive pediatric low-grade brainstem glioma that initially responded to chemotherapy but later recurred, prompting molecularly guided targeted therapy complicated by treatment-related toxicities.
Nicholas Whipple, MD, MPH, reviews a case of extensive pediatric optic pathway glioma with progression on chemotherapy and MEK inhibition, highlighting the role of molecular testing, BRAF/MEK-targeted therapy, and considerations for treatment selection at recurrence.
Mohamed Shebl Abdelbaki, MD, presents a case of a 9-year-old girl with unresectable BRAF V600E–mutant thalamic pilocytic astrocytoma who experienced severe pyrexia and treatment intolerance on dabrafenib plus trametinib, prompting consideration of alternative therapeutic options.
Matthew Cascio, DO, presents a case of a 3-month-old infant with a bilateral optic pathway glioma that progressed on frontline carboplatin and was subsequently found to be a BRAF V600E–mutated pilocytic astrocytoma.
Lindsey Hoffman, DO, presents a case of a 10-year-old girl with an unresectable BRAF V600E–mutated brainstem ganglioglioma causing obstructive hydrocephalus and visual symptoms, highlighting treatment considerations when further surgical resection is not feasible.
Ashley Margol, MD, MS, presents a case of a 7-year-old girl with a KIAA1549-BRAF fusion–positive pilocytic astrocytoma that remained stable during and after carboplatin-vincristine therapy before progressing nearly 2 years later with new neurologic symptoms requiring additional treatment.
Mohamed Shebl Abdelbaki, MD, presents a case of a 1-year-old boy with a KIAA1549-BRAF fusion–positive brainstem ganglioglioma that demonstrated significant radiographic progression after 3 months of carboplatin and vincristine therapy, prompting consideration of alternative treatment strategies.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
